ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 450

ACPA-positive versus ACPA-negative Rheumatoid Arthritis: Two Distinct Erosive Disease Entities on Radiography and Ultrasonography

Julien Grosse1, Edem Allado 1, Camille Roux 1, Audrey Pierreisnard 2, Marion Couderc 3, Isabelle Clerc-Urmès 1, Thomas Remen 1, Eliane Albuisson 4, Marcelo De Carvalho 1, Isabelle Chary-Valckenaere 4 and Damien Loeuille 5, 1Centre Hospitalier Universitaire de Nancy, Nancy, France, 2APHP, Paris, France, 3CHU G.Montpied, Clermont Ferrand, France, 4Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, 5Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-citrullinated protein/peptide antibodies (ACPA), erosion, radiography and ultrasonography, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose:

Several studies have shown that ACPA-positive (ACPA+) patients were more likely to develop erosive disease on radiography (RX) than ACPA-negative (ACPA-) patients, but it has never been demonstrated on ultrasonography (US). The characteristics of bone erosions on both RX and US according to ACPA status has never been studied before. The objective of this study was to assess the prevalence, localization and severity of bone erosions on RX and US according to ACPA status in patients with rheumatoid arthritis (RA).

Methods:

78 patients with ACPA+ RA and 30 patients with ACPA- RA fulfilling the ACR 1987 and/or ACR/EULAR 2010 criteria were consecutively included. On RX, a modified Sharp erosion score (SHSe) was evaluated by two blinded readers and one adjudicator for discordant cases (number of eroded joints ≤ three). On US, erosions were scored on six bilateral joints (MCP2,3,5; MTP2,3,5) with a four-point scale to calculate the total US score for erosions (USSe).

Results: On RX, 33 ACPA+ RA patients (42.3%) and 4 ACPA- RA patients (13.3%) had an erosive disease according to the EULAR 2013 definition criteria. On US, 61 and 63 ACPA+ RA patients (78.2% and 80.8%) versus 14 and 10 ACPA- RA patients (46.7% and 33.3%) had an erosive disease according to the following two definitions: the presence of at least two eroded joint facets (def1) or at least one grade 2 eroded joint facet (def2), respectively.
Erosion patterns were different between ACPA+ RA patients and ACPA- RA patients. On RX, erosions were preferentially observed in MTP joints in the ACPA+ group and in wrists in the ACPA- group (Figure 1). On US, erosions were preferentially found in the lateral facets of MTP5 joints, followed by MCP2 and MCP5 joints in both groups (Figure 2).
On both RX and US, the most discriminating joint between the two groups was MTP5, especially in cases with bilateral erosion (17 ACPA+ RA patients versus 0 ACPA- RA patients on RX, 45 ACPA+ RA patients versus 1 ACPA- RA patient on US; p< 0.001).
The mean total SHSe were 15.3±22.1 and 4.1±8.3 in the ACPA+ and ACPA- groups, respectively (p< 0.001). The mean total USSe were 12.2±11.7 in the ACPA+ group and 2.8±4.4 in the ACPA- group (p< 0.001).
Based on multivariate analyses, ACPA+ status was associated with erosive RA on RX according to the EULAR 2013 definition criteria (OR 4.4 (95% CI 1.2-16.4)), and on US according to def1 (OR 3.7 (95% CI 1.4-9.9)) and def2 (OR 9.0 (95% CI 2.8-28.4)).

Conclusion: Compared to ACPA- RA, ACPA+ RA is associated independently with more severe erosive disease on RX and US. Both US and RX bilateral erosions in MTP5 joints are highly discriminant for ACPA+ RA patients (97.8% in US, 100% in RX).


SHSe

Figure 1: Topography of erosions according to the mean SHSe score for ACPA-positive -ACPA+- and ACPA-negative -ACPA– Rheumatoid Arthritis


USSeFigure

Figure 2: Topography of erosions according to the mean USSe score for ACPA-positive -ACPA+- and ACPA-negative -ACPA– Rheumatoid Arthritis


Disclosure: J. Grosse, None; E. Allado, None; C. Roux, None; A. Pierreisnard, None; M. Couderc, None; I. Clerc-Urmès, None; T. Remen, None; E. Albuisson, None; M. De Carvalho, None; I. Chary-Valckenaere, None; D. Loeuille, None.

To cite this abstract in AMA style:

Grosse J, Allado E, Roux C, Pierreisnard A, Couderc M, Clerc-Urmès I, Remen T, Albuisson E, De Carvalho M, Chary-Valckenaere I, Loeuille D. ACPA-positive versus ACPA-negative Rheumatoid Arthritis: Two Distinct Erosive Disease Entities on Radiography and Ultrasonography [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/acpa-positive-versus-acpa-negative-rheumatoid-arthritis-two-distinct-erosive-disease-entities-on-radiography-and-ultrasonography/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acpa-positive-versus-acpa-negative-rheumatoid-arthritis-two-distinct-erosive-disease-entities-on-radiography-and-ultrasonography/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology